The chemical class termed LALP1 Inhibitors encompasses a spectrum of compounds designed to modulate the activity of LALP1, a protein involved in purinergic signaling pathways. The primary action of these inhibitors is focused on interfering with the functional dynamics of LALP1, particularly in relation to its role in hydrolyzing extracellular nucleotides and regulating purinergic signaling. This inhibition can occur through various mechanisms, targeting different aspects of LALP1's involvement in cellular processes. One key approach involves altering the levels or actions of extracellular nucleotides such as ATP, ADP, and adenosine, which are substrates or products in reactions catalyzed by LALP1. By modulating the availability or effectiveness of these molecules, the inhibitors can alter the purinergic signaling cascades that LALP1 influences. This type of inhibition is significant because it can impact the signaling pathways that are crucial for various physiological processes, including inflammation, neurotransmission, and vascular functions.
In addition to directly targeting the purinergic signaling processes, inhibitors in this class include compounds that modulate the broader cellular environment in which LALP1 operates. These include influencing the signaling pathways downstream or upstream of LALP1's activity. By affecting these pathways, the inhibitors can create a cellular context that modulates the functional demand for LALP1 or alters its impact on cell signaling. This indirect approach takes into consideration the complex interplay between various signaling components within the cell, highlighting the importance of understanding the broader context of LALP1's role. Furthermore, these inhibitors showcase the potential for indirect modulation of enzyme function, providing an avenue for influencing cellular mechanisms in situations where the direct targets and roles of enzymes are not fully elucidated. The development of LALP1 inhibitors, therefore, represents a nuanced approach to understanding and influencing the mechanisms of purinergic signaling at a cellular level. These inhibitors serve as valuable tools for probing the function of LALP1 and offer insights into the complex mechanisms of nucleotide metabolism and signaling. By targeting both the direct activities of LALP1 and the broader network of interactions and pathways in which it operates, LALP1 inhibitors exemplify the intricate strategies required for effective modulation of key components within cellular signaling systems.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Could possibly inhibit LALP1 by interacting with purinergic receptors, thereby modulating downstream effects of nucleotide hydrolysis. | ||||||
Foretinib | 849217-64-7 | sc-364492 | 5 mg | $129.00 | 6 | |
Could possibly inhibit LALP1 by serving as a competitive antagonist at purinergic receptors, affecting ATP-mediated signaling. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $133.00 | 20 | |
Could possibly inhibit LALP1 by affecting calcium signaling downstream of purinergic receptor activation. | ||||||
ZM 241385 | 139180-30-6 | sc-361421 sc-361421A | 5 mg 25 mg | $90.00 $349.00 | 1 | |
Could possibly inhibit LALP1 by acting as an antagonist at adenosine A2A receptors, modulating adenosine signaling. | ||||||
PD 116,948 | 102146-07-6 | sc-200115 sc-200115A | 25 mg 100 mg | $122.00 $224.00 | 6 | |
Could possibly inhibit LALP1 by inhibiting adenosine A1 receptors, influencing pathways related to nucleotide signaling. | ||||||
SCH 58261 | 160098-96-4 | sc-204272 sc-204272A | 10 mg 50 mg | $195.00 $825.00 | ||
Could possibly inhibit LALP1 by blocking adenosine A2A receptors, affecting signaling pathways post-nucleotide hydrolysis. |